#TILs : not only prognostic in TNBC. In a biomarker analysis of TRAIN2, among 389 patients with stage II-III HER2+ BC receiving neoadjuvant chemo + dual HER2 blockade, 13% had high TILs (≥60%) and experienced a 3-year iDFS of 100% (vs 92% if TILs <60%). nature.com/articles/s4152…

Out on JAMA 🚨
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer

In patients with early-stage Triple Negative #BreastCancer who did not undergo adjuvant or neoadjuvant chemotherapy🧪

➡️breast cancer tissue with a higher abundance of TIL levels was…

Excited to finally see this work come out online Nature Portfolio. In this work we identify FOXO1 overexpression as a strategy to improve CAR T cell persistence and metabolic function using CAR T derived from mice, healthy donors and cancer patients.

nature.com/articles/s4158…

see out latest review article #TILs #immunotherapy #breastcancer
'The Anti-Cancer Immune Response in Breast Cancer: Current and Emerging Biomarkers and Treatments'
free link for 40days
authors.elsevier.com/a/1ioXj8Z12yXi…

👏👏latest from TILs Working Group #breastcancer #TILs

See data from NeoPact and NeoN data

Very interesting and useful! Will be cited for years to come. Helpful in de-escalation.

1) we should study chemo elimination in small high TIL tumors (underway)

2) for T1c tumors could help decide neo v adjuvant and which regimen

Congrats to Christine Desmedt Tatjana Geukens highlighting efforts of CASCADE Peter Mac Cancer Centre Peter Savas Peter Mac Research

Out in Cell - Complexities of cancer research- massive effort thanks to Science and Innovation at Cancer Research UK authors.elsevier.com/c/1iqgjL7PXqPxO
Peter Mac Cancer Centre Peter Mac Research Cell

Thank you to all the patients BreastCancerTrials ETOP IBCSG Partners Foundation Peter Mac Cancer Centre #bcsm
Let’s optimize use of chemo and IO for #tnbc

#precisiononcology #breastcancer #pik3ca 👏👏 for targeted therapy- 1L triple therapy seems likely. #SABCS23

Aside trials testing Innovations, there is a need for trials testing pragmatic questions in oncology. These trials must ↘️↘️ the nb of data collected & bureaucracy. This is 1 of the 4 pillars of clinical research strategy Gustave Roussy 1/2 thelancet.com/journals/lance…

Shows that even PCR #TNBC patients with clinical stage 3 at diagnosis still need more work #SABCS23

KATHERINE trial update:
-impressive 13.7% absolute gain in IDFS at 7y with TDM1
-4.7% absolute gain in OS, with further f/u ongoing
-half of distant events occur in CNS - reinforces importance of COMPASS-RD clinical trial testing TDM1-tucatinib
#SABCS23

Excellent presentation 👏👏👏by Nicholas Zdenkowski LBA3-03
#SABCS23

😂 Gen X selfies
We missed you FabriceAndre SABCS #sabcs23

Should we be treating ER positive breast cancer with immunotherapy?
Dr. Virginia Kaklamani, #SABCS23 co-director, explores this question with Dr. Sherene Loi in this episode of SABCS Snippets. Watch now:
VIRGINIA KAKLAMANI Sherene Loi, MD AACR UT Health San Antonio MD Anderson youtu.be/H9vjg7hhyyI?si…

👏👏Great results for patients- nil further RT needed - interesting adverse signal for #TNBC maybe important to not kill lymphocytes which are very radiation sensitive in an immunogenic - #breastcancer type? 🤔

Published synchronously with #SABCS23 Reshma Jagsi Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA ascopubs.org/doi/10.1200/JC… Journal of Clinical Oncology SABCS OncoAlert

Patients with HR-positive BC can use fertility preservation and assisted reproductive technologies to conceive without an increased short-term risk of recurrence.
Results of the IBCSG 48-14/BIG 8-13 POSITIVE trial presented today at #sabcs2023